BMS-986421 / BMS - LARVOL DELTA

A Phase 1, First-in-Human Study of BMS-986421 in Healthy Participants (clinicaltrials.gov) - P1 | N=46 | Terminated | Sponsor: Bristol-Myers Squibb | N=80 ➔ 46 | Recruiting ➔ Terminated; Adverse change in the risk/benefit.

Enrollment change • Trial termination